OBJECTIVE: To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA). METHODS: Thirty-two RA patients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days. RESULTS: There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity. CONCLUSION: Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RA patients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.
OBJECTIVE: To investigate the effects of chimeric CD4 monoclonal antibody cM-T412 treatment in patients with rheumatoid arthritis (RA). METHODS: Thirty-two RApatients received daily doses of 10, 50, or 100 mg of cM-T412 intravenously for 7 days. RESULTS: There was a sustained decrease in the number of CD4+ T lymphocytes in all patients. Those who received 50 mg and 100 mg of the antibody experienced significant reductions in disease activity. CONCLUSION: Treatment with cM-T412 appears to have a dose-dependent beneficial effect in RApatients. The clinical effects of cM-T412 are independent of the depressed numbers of circulating CD4+ T cells.
Authors: D J Veale; R J Reece; W Parsons; A Radjenovic; P J O'Connor; C S Orgles; E Berry; J P Ridgway; U Mason; A W Boylston; W Gibbon; P Emery Journal: Ann Rheum Dis Date: 1999-06 Impact factor: 19.103
Authors: J D Isaacs; N Burrows; M Wing; M T Keogan; P R Rebello; R A Watts; R J Pye; P Norris; B L Hazelman; G Hale; H Waldmann Journal: Clin Exp Immunol Date: 1997-11 Impact factor: 4.330